Following an 18.49% surge in its share price yesterday, Burning Rock Biotech Limited (BNR.US) climbed over 10% again on Thursday, reaching $31.483. Recently, the company presented two research findings at the San Antonio Breast Cancer Symposium (SABCS) and the ASCO Gastrointestinal Cancers Symposium (ASCO-GI), focusing on the clinical application of liquid biopsy technology for breast cancer (BC) and colorectal cancer (CRC). These presentations offered novel solutions for detecting low-frequency mutations and minimal residual disease (MRD), contributing the company's expertise to the exploration of innovative precision oncology diagnostics and therapies. While traditional tissue biopsies are invasive and often fail to meet the clinical need for long-term BC monitoring, liquid biopsy provides a minimally invasive alternative by analyzing circulating tumor DNA (ctDNA) in the blood. Addressing the clinical challenge of detecting ctDNA when tumor burden is low, Burning Rock developed OncoCompass, an ultra-deep targeted sequencing technology that incorporates machine learning to enhance the accuracy and reliability of low-frequency ctDNA detection. By innovatively combining ultra-deep sequencing with machine learning, Burning Rock's OncoCompass overcomes the technical barriers of low-abundance ctDNA detection, effectively tackling core issues in BC treatment efficacy monitoring and recurrence warning. This provides a practical mutation detection tool for BC patients with low tumor levels, further expanding the application boundaries of liquid biopsy in the field of precision oncology.